Evidence exists to support the crucial involvement of COX-2 in a number of pathologies, like inflammation,21 cancer,22–24 neurological illnesses,25 and multidrug resistance.26 Thus, one of the main areas of focus for both academic research and the pharmaceutical sector is particularly COX-2 inhibitors' development as anti-inflammatory and anti-tumor medications. The gene discussed is PTGS2; the disease is neoplasm.